The cluster is dominated by a single 10% owner buying post-merger-announcement, which is a modest vote of confidence in the deal's value. However, the other 10% owner sold a trivial amount, likely for tax/vesting reasons. The merger with Serapha Bio is the dominant catalyst — monitor the proxy statement and stockholder vote for deal completion. The insider buying does not change the deal thesis but reduces the risk of insider pessimism.
Price Chart
Executive Summary
Two 10% owners at Boundless Bio (BOLD) traded in opposite directions in the same window: Kevin Tang bought ~$203K worth of shares open-market, while Keith Crandell sold $40K (combined with a derivative exercise). These trades occurred 8-9 days after the company signed a definitive merger agreement to acquire Serapha Bio, making the insider activity highly likely informed by the pending deal. The net dollar direction is buying ($163K), but the cluster is small relative to the $56M market cap (~0.36%), and the sell side is trivial.
Key Financial Metrics
Key Facts
- Kevin Tang (10% owner) purchased 81,433 shares open-market for ~$202,768 between July 1-2, 2026.
- Keith Crandell (10% owner) sold 16,000 shares open-market for $39,840 on July 1, 2026, while also exercising derivatives for 16,000 shares at $1.03 ($16,480) and 16,000 shares at $0 (non-cash).
- The cluster occurred 8-9 days after Boundless Bio filed a merger agreement (8-K, June 23) to acquire Serapha Bio.
- Total open-market purchase value ($202,768) is ~0.36% of the $56M market cap — modest but notable for a micro-cap.
- The sell side ($39,840) is ~0.07% of market cap — trivial and likely liquidity/vesting-driven.
- Analyst consensus is 0% bullish (4 Hold, 3 Sell/Strong Sell), indicating low Street conviction.
Financial Impact
Net insider buying of ~$163K (purchases minus sales) represents ~0.29% of the $56M market cap. The buy side is ~0.36% of market cap.
Risk Factors
- Merger with Serapha Bio may not close (stockholder approval, regulatory conditions).
- Micro-cap biotech with low analyst coverage and 0% bullish consensus — high execution risk.
- Insider selling by Crandell, while small, could indicate personal liquidity needs or a less bullish view on the combined entity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BOLD-1783407978094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | — | awaiting T+20 | — | — |
Oct 26, 2026 today | 425 | — | awaiting T+20 | — | — |
Oct 8, 2026 18d ago | S-4 | $2.53 | awaiting T+20 | — | $2.41 (+4.74%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.41 (−14.23%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.41 (−3.98%) |
Jul 6, 2026 16w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.41 (−3.60%) |
Jun 29, 2026 17w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.41 (−3.60%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.41 (+67.36%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.41 (−67.36%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.41 (+50.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers